CDNA CAREDX INC

CareDx Joins National Kidney Foundation on World Kidney Day to Support Kidney Transplant Community

CareDx Joins National Kidney Foundation on World Kidney Day to Support Kidney Transplant Community

CareDx CMO to Chair Upcoming NKF San Francisco Kidney Walk

SOUTH SAN FRANCISCO, Calif., March 12, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leader in precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high value healthcare solutions for transplant patients and caregivers, today honors World Kidney Day and reinforces commitment to the kidney transplant community.

World Kidney Day is a global campaign aimed at raising awareness of the importance of our kidneys to our overall health and to reduce the frequency and impact of kidney disease and its associated health problems worldwide. CareDx celebrates World Kidney Day by hosting the National Kidney Foundation Walk Breakfast to raise awareness and funds for the Kidney Walk in San Francisco.

CareDx’s Chief Marketing Officer, Sasha King, was announced by NKF as the 2020 San Francisco Kidney Walk Chair. The Kidney Walk will be held on Sunday, June 14th at the Embarcadero Plaza.

“CareDx is a true partner to the transplant community, with incredible patient centricity. I applaud their focus on patient advocacy and dedication to kidney care,” said Doris Lew, National Kidney Foundation Community Outreach Coordinator and kidney transplant recipient.

“CareDx is deeply entrenched with the kidney community, and we are glad to bring a focus on transplant education to World Kidney Day,” said Sasha King, Chief Marketing Officer. “I am honored to be the San Francisco chair for the 2020 Kidney Walk. I look forward to continue working with the NKF to provide kidney transplant patients with the resources and innovations to help improve their lives.”

About CareDx

CareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey, and is the leading provider of genomics-based information for transplant patients. For more information, please visit:

CONTACTS:

CareDx, Inc.

Sasha King

Chief Marketing Officer

415-287-2393

 

Investor Relations

Greg Chodaczek

646-924-1769

   

EN
12/03/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CAREDX INC

CareDx Inc: 1 director

A director at CareDx Inc sold 16,700 shares at 14.128USD and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

CareDx Receives CE Mark for AlloSeq HCT for Use in Hematopoietic Cell ...

CareDx Receives CE Mark for AlloSeq HCT for Use in Hematopoietic Cell Transplantation CareDx Expands Transplant Portfolio in Europe SOUTH SAN FRANCISCO, Calif., May 24, 2022 (GLOBE NEWSWIRE) --  CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that it has received CE marking for its AlloSeq HCT chimerism testing kit and AlloSeq HCT interpretation software for use in patients who have received hematopoieti...

 PRESS RELEASE

CareDx Sponsored ISHLT Innovation Challenge Award Tackles Chronic Lung...

CareDx Sponsored ISHLT Innovation Challenge Award Tackles Chronic Lung Allograft Dysfunction Donor-Derived Cell-Free DNA will be Used to Evaluate Treatment to Improve Lung Transplant Outcomes SOUTH SAN FRANCISCO, Calif., May 18, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the International Society for Heart and Lung Transplantation (ISHLT) has selected Dr. Berta Sáez-Gim...

 PRESS RELEASE

In CareDx-Initiated IP Litigation Against Natera, Natera Now Drops 1 o...

In CareDx-Initiated IP Litigation Against Natera, Natera Now Drops 1 of 2 Patents Originally Asserted Against CareDx Natera Recycles Old IP for New Lawsuits SOUTH SAN FRANCISCO, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that Natera has just dropped one of their two patents originally asserted against CareDx. At the same time, Natera asserted two patents tha...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch